Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

被引：307

作者：

Goff, Stephanie L. ^{[1
]}

Dudley, Mark E. ^{[3
]}

Citrin, Deborah E. ^{[1
]}

Somerville, Robert P. ^{[1
]}

Wunderlich, John R. ^{[1
]}

Danforth, David N. ^{[1
]}

Zlott, Daniel A. ^{[2
]}

Yang, James C. ^{[1
]}

Sherry, Richard M. ^{[1
]}

Kammula, Udai S. ^{[1
]}

Klebanoff, Christopher A. ^{[1
]}

Hughes, Marybeth S. ^{[1
]}

Restifo, Nicholas P. ^{[1
]}

Langhan, Michelle M. ^{[1
]}

Shelton, Thomas E. ^{[1
]}

Lu, Lily ^{[1
]}

Kwong, Mei Li M. ^{[1
]}

Ilyas, Sadia ^{[1
]}

Klemen, Nicholas D. ^{[1
]}

Payabyab, Eden C. ^{[1
]}

Morton, Kathleen E. ^{[1
]}

Toomey, Mary Ann ^{[1
]}

Steinberg, Seth M. ^{[1
]}

White, Donald E. ^{[1
]}

Rosenberg, Steven A. ^{[1
]}

机构：

[1] NCI, NIH, Bethesda, MD 20892 USA

[2] NIH, Ctr Clin, Bethesda, MD 20892 USA

[3] Novartis Inst BioMed Res, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 20期

基金：

美国国家卫生研究院;

关键词：

CELL TRANSFER THERAPY; T-CELLS; UNTREATED MELANOMA; IPILIMUMAB; CANCER; INTERLEUKIN-2; CHEMOTHERAPY; NIVOLUMAB; ANTI-PD-1; EFFICACY;

D O I：

10.1200/JCO.2016.66.7220

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%). Addition and intensification of total body irradiation (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objective partial and complete response (CR) rates. Here, we evaluated the importance of adding TBI to the adoptive transfer of tumor-infiltrating lymphocytes (TIL) in a randomized fashion. Patients and Methods A total of 101 patients with metastatic melanoma, including 76 patients with M1c disease, were randomly assigned to receive nonmyeloablative chemotherapy with or without 1,200 cGy TBI before transfer of tumor-infiltrating lymphcytes. Primary end points were CR rate (as defined by Response Evaluation Criteria in Solid Tumors v1.0) and overall survival (OS). Clinical and laboratory data were analyzed for correlates of response. Results CR rates were 24% in both groups (12 of 50 v 12 of 51), and OS was also similar (median OS, 38.2 v 36.6 months; hazard ratio, 1.11; 95% CI, 0.65 to 1.91; P=.71). Thrombotic microangiopathy was an adverse event unique to the TBI arm and occurred in 13 of 48 treated patients. With a median potential follow-up of 40.9 months, only one of 24 patients who achieved a CR recurred. Conclusion Adoptive cell transfer can mediate durable complete regressions in 24% of patients with metastatic melanoma, with median survival. 3 years. Results were similar using chemotherapy preparative regimens with or without addition of TBI. (C) 2016 by American Society of Clinical Oncology

引用

页码：2389 / U145

页数：16

共 35 条

[1]

Agresti A., 1990, CATEGORICAL DATA ANA

[2]

[Anonymous], 2015, CANC FACTS FIG 2015

[3]

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Itzhaki, Orit ;

Treves, Avraham J. ;

Zippel, Douglas B. ;

Levy, Daphna ;

Kubi, Adva ;

Shoshani, Noa ;

Zikich, Dragoslav ;

Ohayon, Yaara ;

Ohayon, Daniel ;

Shalmon, Bruria ;

Markel, Gal ;

Yerushalmi, Ronit ;

Apter, Sara ;

Ben-Nun, Alon ;

Ben-Ami, Eytan ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2013, 19 (17) :4792-4800

[4]

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].

Diem, S. ;

Kasenda, B. ;

Spain, L. ;

Martin-Liberal, J. ;

Marconcini, R. ;

Gore, M. ;

Larkin, J. .

BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261

[5]

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens [J].

Dudley, Mark E. ;

Yang, James C. ;

Sherry, Richard ;

Hughes, Marybeth S. ;

Royal, Richard ;

Kammula, Udai ;

Robbins, Paul F. ;

Huang, JianPing ;

Citrin, Deborah E. ;

Leitman, Susan F. ;

Wunderlich, John ;

Restifo, Nicholas P. ;

Thomasian, Armen ;

Downey, Stephanie G. ;

Smith, Franz O. ;

Klapper, Jacob ;

Morton, Kathleen ;

Laurencot, Carolyn ;

White, Donald E. ;

Rosenberg, Steven A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5233-5239

[6]

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].

Dudley, ME ;

Wunderlich, JR ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Restifo, NP ;

Royal, RE ;

Kammula, U ;

White, DE ;

Mavroukakis, SA ;

Rogers, LJ ;

Gracia, GJ ;

Jones, SA ;

Mangiameli, DP ;

Pelletier, MM ;

Gea-Banacloche, J ;

Robinson, MR ;

Berman, DM ;

Filie, AC ;

Abati, A ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357

[7]

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients [J].

Dudley, ME ;

Wunderlich, JR ;

Shelton, TE ;

Even, J ;

Rosenberg, SA .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :332-342

[8]

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma [J].

Dudley, ME ;

Wunderlich, JR ;

Yang, JC ;

Hwu, P ;

Schwartzentruber, DJ ;

Topalian, SL ;

Sherry, RM ;

Marincola, FM ;

Leitman, SF ;

Seipp, CA ;

Rogers-Freezer, L ;

Morton, KE ;

Nahvi, A ;

Mavroukakis, SA ;

White, DE ;

Rosenberg, SA .

JOURNAL OF IMMUNOTHERAPY, 2002, 25 (03) :243-251

[9]

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].

Ferrucci, P. F. ;

Ascierto, P. A. ;

Pigozzo, J. ;

Del Vecchio, M. ;

Maio, M. ;

Cappellini, G. C. Antonini ;

Guidoboni, M. ;

Queirolo, P. ;

Savoia, P. ;

Mandala, M. ;

Simeone, E. ;

Valpione, S. ;

Altomonte, M. ;

Spagnolo, F. ;

Cocorocchio, E. ;

Gandini, S. ;

Giannarelli, D. ;

Martinoli, C. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738

[10]

Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines [J].

Geginat, J ;

Lanzavecchia, A ;

Sallusto, F .

BLOOD, 2003, 101 (11) :4260-4266

← 1 2 3 4 →